AIM: Yttrium-90 ((90)Y) ibritumomab tiuxetan (Zevalin) radioimmunotherapy is an effective treatment for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL), with overall response rates ranging from 74% to 82%. This retrospective analysis was conducted to determine the number of patients achieving long-term durable responses with (90)Y ibritumomab tiuxetan treatment. MATERIALS AND METHODS: The medical records of patients (n = 211) with relapsed, refractory, or transformed indolent CD20+ B-cell NHL who were treated with 90Y ibritumomab tiuxetan were reviewed. Time to progression (TTP) of > or =12 months was noted in 78 patients (37%), who were identified as long-term responders and were further characterized. RESULTS: Median age of the long-term responders was 58 years (range, 24-80 years) with 44% over 60 years, and 55% were male. Notably, 59% of patients had received > or =2 prior regimens, 33% had received > or =3 prior regimens, and 37% had failed to respond to immediate prior therapy. Median response duration was 28.1 months (range, 10.5-80.3+ months). Median TTP was 29.3 months (range, 12.1-81.5+ months). In patients with ongoing response, median TTP was 53.9 months (range, 49-82+ months). CONCLUSIONS: (90)Y ibritumomab tiuxetan produces durable long-term responses in patients with relapsed/refractory B-cell NHL. Failure to respond to prior therapy does not preclude achieving a long-term response with 90Y ibritumomab tiuxetan.
AIM: Yttrium-90 ((90)Y) ibritumomab tiuxetan (Zevalin) radioimmunotherapy is an effective treatment for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL), with overall response rates ranging from 74% to 82%. This retrospective analysis was conducted to determine the number of patients achieving long-term durable responses with (90)Y ibritumomab tiuxetan treatment. MATERIALS AND METHODS: The medical records of patients (n = 211) with relapsed, refractory, or transformed indolent CD20+ B-cell NHL who were treated with 90Y ibritumomab tiuxetan were reviewed. Time to progression (TTP) of > or =12 months was noted in 78 patients (37%), who were identified as long-term responders and were further characterized. RESULTS: Median age of the long-term responders was 58 years (range, 24-80 years) with 44% over 60 years, and 55% were male. Notably, 59% of patients had received > or =2 prior regimens, 33% had received > or =3 prior regimens, and 37% had failed to respond to immediate prior therapy. Median response duration was 28.1 months (range, 10.5-80.3+ months). Median TTP was 29.3 months (range, 12.1-81.5+ months). In patients with ongoing response, median TTP was 53.9 months (range, 49-82+ months). CONCLUSIONS: (90)Y ibritumomab tiuxetan produces durable long-term responses in patients with relapsed/refractory B-cell NHL. Failure to respond to prior therapy does not preclude achieving a long-term response with 90Y ibritumomab tiuxetan.
Authors: Robert M Sharkey; Habibe Karacay; Samuel Litwin; Edmund A Rossi; William J McBride; Chien-Hsing Chang; David M Goldenberg Journal: Cancer Res Date: 2008-07-01 Impact factor: 12.701
Authors: Damian J Green; Mazyar Shadman; Jon C Jones; Shani L Frayo; Aimee L Kenoyer; Mark D Hylarides; Donald K Hamlin; D Scott Wilbur; Ethan R Balkan; Yukang Lin; Brian W Miller; Sofia H L Frost; Ajay K Gopal; Johnnie J Orozco; Theodore A Gooley; Kelly L Laird; Brian G Till; Tom Bäck; Brenda M Sandmaier; John M Pagel; Oliver W Press Journal: Blood Date: 2015-01-27 Impact factor: 22.113
Authors: Anastasia Pantelias; John M Pagel; Nathan Hedin; Laura Saganic; Shani Wilbur; Donald K Hamlin; D Scott Wilbur; Yukang Lin; Diane Stone; Don Axworthy; Ajay K Gopal; Oliver W Press Journal: Blood Date: 2007-02-15 Impact factor: 22.113
Authors: Thomas E Witzig; Gregory A Wiseman; Matthew J Maurer; Thomas M Habermann; Ivana N M Micallef; Grzegorz S Nowakowski; Stephen M Ansell; Joseph P Colgan; David J Inwards; Luis F Porrata; Brian K Link; Clive S Zent; Patrick B Johnston; Tait D Shanafelt; Cristine Allmer; Yan W Asmann; Mamta Gupta; Zuhair K Ballas; Brian J Smith; George J Weiner Journal: Am J Hematol Date: 2013-06-12 Impact factor: 10.047
Authors: John M Pagel; Yukang Lin; Nathan Hedin; Anastasia Pantelias; Donald Axworthy; Diane Stone; Don K Hamlin; D Scott Wilbur; Oliver W Press Journal: Blood Date: 2006-03-23 Impact factor: 22.113
Authors: S A Jacobs; A M Harrison; S H Swerdlow; K A Foon; N Avril; N Vidnovic; J Joyce; N DeMonaco; K S McCarty Journal: Mol Imaging Biol Date: 2008-09-05 Impact factor: 3.488